Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...

Edwards Lifesciences has received CE Mark approval for expanding the use of the Sapien 3 transcatheter heart valve to patients with severe, symptomatic aortic stenosis at intermediate risk for ...

Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s ...

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...

(UPDATED) CHICAGO, IL—The latest iteration of the FDA-approved balloon-expandable transcatheter aortic valve has proven itself superior to surgery among intermediate-risk patients in a ...

NEWBURY, May 8 2024 -- Edwards Lifesciences today announced the UK launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough ...

This is for you, PrimalScript fans: My contacts at Sapien allowed me to leak a few teasers about the next version of PrimalScript that will hit the streets around August 1. The new 2007 release of ...

The Edwards SAPIEN 3 Transcatheter Pulmonary Valve (“TPV”) system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with extreme pulmonary ...

Please provide your email address to receive an email when new articles are posted on . Edwards Lifesciences has announced that its second-generation transcatheter valve, Sapien XT, has received FDA ...